Roquefort Therapeutics (COIL) Competitors GBX 10.12 -0.88 (-7.95%) As of 12:12 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock COIL vs. TILS, VSN, MPH, BVXP, and FARNShould you buy Roquefort Therapeutics stock or one of its competitors? MarketBeat compares Roquefort Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Roquefort Therapeutics include Tiziana Life Sciences (TILS), Verseon (VSN), Mereo BioPharma Group plc (MPH.L) (MPH), Bioventix (BVXP), and Faron Pharmaceuticals Oy (FARN). These companies are all part of the "biotechnology" industry. COIL vs. TILSCOIL vs. VSNCOIL vs. MPHCOIL vs. BVXPCOIL vs. FARNHow does Roquefort Therapeutics compare to Tiziana Life Sciences?Roquefort Therapeutics (LON:COIL) and Tiziana Life Sciences (LON:TILS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk. Does the media favor COIL or TILS? In the previous week, Tiziana Life Sciences had 2 more articles in the media than Roquefort Therapeutics. MarketBeat recorded 2 mentions for Tiziana Life Sciences and 0 mentions for Roquefort Therapeutics. Tiziana Life Sciences' average media sentiment score of 0.58 beat Roquefort Therapeutics' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Roquefort Therapeutics Neutral Tiziana Life Sciences Positive Which has higher valuation and earnings, COIL or TILS? Tiziana Life Sciences has lower revenue, but higher earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoquefort TherapeuticsN/AN/A-£1.52M-£6.30N/ATiziana Life Sciences-£3.60M0.00N/A-£16.30N/A Is COIL or TILS more profitable? Tiziana Life Sciences has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Tiziana Life Sciences' return on equity of 0.00% beat Roquefort Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Roquefort Therapeutics-57,057.07% -18.30% -15.86% Tiziana Life Sciences N/A N/A N/A Do institutionals & insiders believe in COIL or TILS? 1.2% of Roquefort Therapeutics shares are held by institutional investors. 22.6% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryRoquefort Therapeutics and Tiziana Life Sciences tied by winning 5 of the 10 factors compared between the two stocks.How does Roquefort Therapeutics compare to Verseon?Roquefort Therapeutics (LON:COIL) and Verseon (LON:VSN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Does the media prefer COIL or VSN? In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score. Company Overall Sentiment Roquefort Therapeutics Neutral Verseon Neutral Is COIL or VSN more profitable? Verseon has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Verseon's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Roquefort Therapeutics-57,057.07% -18.30% -15.86% Verseon N/A N/A N/A Do institutionals and insiders have more ownership in COIL or VSN? 1.2% of Roquefort Therapeutics shares are held by institutional investors. 22.6% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has preferable earnings & valuation, COIL or VSN? Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoquefort TherapeuticsN/AN/A-£1.52M-£6.30N/AVerseonN/AN/AN/A-£14.30N/A SummaryRoquefort Therapeutics beats Verseon on 4 of the 7 factors compared between the two stocks.How does Roquefort Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?Mereo BioPharma Group plc (MPH.L) (LON:MPH) and Roquefort Therapeutics (LON:COIL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends. Does the media refer more to MPH or COIL? In the previous week, Mereo BioPharma Group plc (MPH.L)'s average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score. Company Overall Sentiment Mereo BioPharma Group plc (MPH.L) Neutral Roquefort Therapeutics Neutral Which has better earnings & valuation, MPH or COIL? Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/ARoquefort TherapeuticsN/AN/A-£1.52M-£6.30N/A Do insiders & institutionals hold more shares of MPH or COIL? 1.2% of Roquefort Therapeutics shares are held by institutional investors. 22.6% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is MPH or COIL more profitable? Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Roquefort Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mereo BioPharma Group plc (MPH.L)N/A N/A N/A Roquefort Therapeutics -57,057.07%-18.30%-15.86% SummaryMereo BioPharma Group plc (MPH.L) beats Roquefort Therapeutics on 4 of the 7 factors compared between the two stocks.How does Roquefort Therapeutics compare to Bioventix?Roquefort Therapeutics (LON:COIL) and Bioventix (LON:BVXP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations. Does the media prefer COIL or BVXP? In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Bioventix'saverage media sentiment score. Company Overall Sentiment Roquefort Therapeutics Neutral Bioventix Neutral Do institutionals and insiders have more ownership in COIL or BVXP? 1.2% of Roquefort Therapeutics shares are owned by institutional investors. Comparatively, 21.1% of Bioventix shares are owned by institutional investors. 22.6% of Roquefort Therapeutics shares are owned by insiders. Comparatively, 6.2% of Bioventix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, COIL or BVXP? Roquefort Therapeutics has a beta of 0.05, meaning that its share price is 95% less volatile than the broader market. Comparatively, Bioventix has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Is COIL or BVXP more profitable? Bioventix has a net margin of 59.30% compared to Roquefort Therapeutics' net margin of -57,057.07%. Bioventix's return on equity of 65.83% beat Roquefort Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Roquefort Therapeutics-57,057.07% -18.30% -15.86% Bioventix 59.30%65.83%54.07% Which has higher earnings & valuation, COIL or BVXP? Bioventix has higher revenue and earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Bioventix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoquefort TherapeuticsN/AN/A-£1.52M-£6.30N/ABioventix£12.54M6.94£8.12M£140.5211.85 SummaryBioventix beats Roquefort Therapeutics on 9 of the 10 factors compared between the two stocks.How does Roquefort Therapeutics compare to Faron Pharmaceuticals Oy?Roquefort Therapeutics (LON:COIL) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk. Do institutionals & insiders believe in COIL or FARN? 1.2% of Roquefort Therapeutics shares are owned by institutional investors. Comparatively, 1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 22.6% of Roquefort Therapeutics shares are owned by company insiders. Comparatively, 3.9% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, COIL or FARN? Roquefort Therapeutics has a beta of 0.05, suggesting that its share price is 95% less volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.109, suggesting that its share price is 11% more volatile than the broader market. Is COIL or FARN more profitable? Faron Pharmaceuticals Oy has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat Roquefort Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Roquefort Therapeutics-57,057.07% -18.30% -15.86% Faron Pharmaceuticals Oy N/A 45.13%-70.00% Which has preferable earnings & valuation, COIL or FARN? Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoquefort TherapeuticsN/AN/A-£1.52M-£6.30N/AFaron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A Does the media prefer COIL or FARN? In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Faron Pharmaceuticals Oy'saverage media sentiment score. Company Overall Sentiment Roquefort Therapeutics Neutral Faron Pharmaceuticals Oy Neutral SummaryRoquefort Therapeutics beats Faron Pharmaceuticals Oy on 5 of the 9 factors compared between the two stocks. Get Roquefort Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COIL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COIL vs. The Competition ExportMetricRoquefort TherapeuticsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£43.12M£466.44M£6.30B£2.79BDividend YieldN/A3.87%2.80%6.16%P/E Ratio-1.613.8420.79365.60Price / SalesN/A7,093.49518.7987,567.35Price / Cash1.4913.1343.1827.89Price / Book2.6584.109.967.63Net Income-£1.52M-£96.07M£3.54B£5.89B7 Day Performance26.56%-0.03%-0.19%-0.02%1 Month Performance26.56%-0.29%-0.63%1.06%1 Year Performance-36.24%70.20%34.10%85.15% Roquefort Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COILRoquefort TherapeuticsN/AGBX 10.13-8.0%N/A-28.8%£43.12MN/AN/A9High Trading VolumeTILSTiziana Life SciencesN/AN/AN/AN/A£113.85M-£3.60MN/A11News CoverageVSNVerseonN/AN/AN/AN/A£112.24MN/AN/AN/AGap UpMPHMereo BioPharma Group plc (MPH.L)N/AN/AN/AN/A£89.76MN/AN/A50Gap DownBVXPBioventixN/AGBX 1,672-1.6%N/A-42.6%£87.36M£12.54M11.9012Gap Up Related Companies and Tools Related Companies TILS Alternatives VSN Alternatives MPH Alternatives BVXP Alternatives FARN Alternatives 4BB Alternatives ORPH Alternatives REDX Alternatives ETX Alternatives HVO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:COIL) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roquefort Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Roquefort Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
